Clinical Trial

A Single-Dose Study to Evaluate Safety and Efficacy of CS-1103 in Participants Receiving a Single Dose of Methamphetamine

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of the study is to evaluate the safety, efficacy, and pharmacokinetics of four single, increasing doses of CS-1103, given by intravenous (IV) infusion in otherwise healthy, non-treatment seeking participants with methamphetamine use disorder in the presence of a clinically relevant dose of methamphetamine HCl (30 mg IV).
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2024-12-03; most recent amendment 2026-07-06.
Status change: Not Yet Recruiting → Recruiting 2026-01-09
Trial Details
NCT Number NCT06721494
Lead Sponsor Clear Scientific, Inc.
Collaborators: National Institute on Drug Abuse (NIDA)
Conditions Methamphetamine Intoxication, Methamphetamine Disorders, Methamphetamine Abuse
Enrollment 40 participants
Start Date 2026-02-05
Primary Completion 2026-09-04 (estimated)
Study Completion 2026-09-11 (estimated)
Updated on ClinicalTrials.gov 2026-07-07